Compound Detail
CHEMBL119385
NEFLAMAPIMOD 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL119385 |
| Name | NEFLAMAPIMOD |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | VEPKQEUBKLEPRA-UHFFFAOYSA-N |
35
Targets
106
Activities
3
Assay Types
22
PK Parameters
20
Publications
7
Known Names
5
Indications
1
Mechanisms
Molecular Properties
436.3
MW (Da)
5.49
ALogP
5
HBA
0
HBD
47.3
PSA (Ų)
0.43
QED
1
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| MAP kinase p38 alpha inhibitor | INHIBITOR | Mitogen-activated protein kinase 14 | ✓ | ✓ |
Indications
Alzheimer Disease Cognitive Dysfunction Dementia Huntington Disease Lewy Body Disease
Activity Summary
Kd 57 meas. best 8.55
IC50 37 meas. best 9.1
Ki 12 meas. best 9.1
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| MAP kinase p38 CHEMBL2094115 | Ki | 9.1 | 9.1 | 0.8 | 1 |
| MAP kinase p38 CHEMBL2094115 | IC50 | 9.1 | 7.448 | 0.8 | 5 |
| Mitogen-activated protein kinase 14 CHEMBL260 | Kd | 8.55 | 8.535 | 2.8 | 4 |
| Mitogen-activated protein kinase 14 CHEMBL260 | Ki | 8.3 | 8.3 | 5.0 | 1 |
| Mitogen-activated protein kinase 14 CHEMBL260 | IC50 | 8.05 | 6.9669 | 9.0 | 13 |
| Mitogen-activated protein kinase 14 CHEMBL2336 | IC50 | 7.66 | 7.66 | 22.0 | 1 |
| THP-1 CHEMBL614245 | IC50 | 7.41 | 7.33 | 39.0 | 2 |
| Mitogen-activated protein kinase 11 CHEMBL3961 | Kd | 7.13 | 7.02 | 74.0 | 3 |
| Blood CHEMBL613416 | IC50 | 6.75 | 6.75 | 177.0 | 1 |
| Tyrosine-protein kinase ABL2 CHEMBL4014 | Kd | 6.66 | 6.0333 | 220.0 | 3 |
| Mitogen-activated protein kinase 11 CHEMBL3961 | Ki | 6.66 | 6.66 | 220.0 | 1 |
| Proto-oncogene tyrosine-protein kinase ROS CHEMBL5568 | Ki | 6.4 | 6.4 | 398.1 | 1 |
| Tyrosine-protein kinase ABL1 CHEMBL1862 | Kd | 6.15 | 5.8155 | 710.0 | 11 |
| Platelet-derived growth factor receptor beta CHEMBL1913 | Kd | 6.06 | 5.4067 | 870.0 | 3 |
| Proto-oncogene tyrosine-protein kinase Src CHEMBL267 | Kd | 6.01 | 5.51 | 980.0 | 3 |
| Ephrin type-B receptor 4 CHEMBL5147 | Kd | 6.0 | 6.0 | 1000.0 | 1 |
| Epithelial discoidin domain-containing receptor 1 CHEMBL5319 | Kd | 5.96 | 5.96 | 1100.0 | 2 |
| Tyrosine-protein kinase Fgr CHEMBL4454 | Kd | 5.92 | 5.9 | 1200.0 | 3 |
| Tyrosine-protein kinase Yes CHEMBL2073 | Kd | 5.8 | 5.7267 | 1600.0 | 3 |
| Ephrin type-B receptor 1 CHEMBL5072 | Kd | 5.8 | 5.505 | 1600.0 | 2 |
| Tyrosine-protein kinase Lyn CHEMBL3905 | Kd | 5.77 | 5.77 | 1700.0 | 2 |
| Tyrosine-protein kinase Lck CHEMBL258 | Kd | 5.75 | 5.4767 | 1800.0 | 3 |
| Ephrin type-A receptor 5 CHEMBL3987 | Kd | 5.72 | 5.72 | 1900.0 | 1 |
| Tyrosine-protein kinase Fyn CHEMBL1841 | Kd | 5.68 | 5.68 | 2100.0 | 2 |
| Ephrin type-A receptor 2 CHEMBL2068 | Kd | 5.68 | 5.68 | 2100.0 | 1 |
| Macrophage colony-stimulating factor 1 receptor CHEMBL1844 | Kd | 5.58 | 5.58 | 2600.0 | 2 |
| Tyrosine-protein kinase Blk CHEMBL2250 | Kd | 5.51 | 5.51 | 3100.0 | 2 |
| Ephrin type-A receptor 8 CHEMBL4134 | Kd | 5.51 | 5.51 | 3100.0 | 1 |
| Tyrosine-protein kinase FRK CHEMBL4223 | Kd | 5.48 | 5.48 | 3300.0 | 1 |
| Ephrin type-A receptor 1 CHEMBL5810 | Kd | 5.33 | 5.33 | 4700.0 | 1 |
| Adenosine receptor A3 CHEMBL256 | Ki | 5.32 | 5.32 | 4831.0 | 1 |
| Sodium-dependent dopamine transporter CHEMBL238 | Ki | 5.19 | 5.19 | 6434.0 | 1 |
| Sodium-dependent dopamine transporter CHEMBL238 | IC50 | 5.09 | 5.09 | 8098.0 | 1 |
| Adenosine receptor A3 CHEMBL256 | IC50 | 5.07 | 5.07 | 8547.0 | 1 |
| Platelet-derived growth factor receptor alpha CHEMBL2007 | Kd | 5.06 | 5.06 | 8800.0 | 1 |
| Unchecked CHEMBL612545 | Ki | 5.01 | 4.7433 | 9767.0 | 3 |
| Ephrin type-A receptor 4 CHEMBL3988 | Kd | 5.0 | 5.0 | 10000.0 | 1 |
| Tyrosine-protein kinase HCK CHEMBL3234 | Kd | 5.0 | 5.0 | 10000.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.0 | 4.7275 | 10000.0 | 4 |
| Alpha-2A adrenergic receptor CHEMBL1867 | Ki | 4.89 | 4.89 | 12813.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | Ki | 4.84 | 4.84 | 14557.0 | 1 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | Ki | 4.69 | 4.69 | 20236.0 | 1 |
| Sodium-dependent noradrenaline transporter CHEMBL222 | IC50 | 4.69 | 4.69 | 20404.0 | 1 |
| Alpha-2B adrenergic receptor CHEMBL1942 | IC50 | 4.5 | 4.5 | 31886.0 | 1 |
| Alpha-2A adrenergic receptor CHEMBL1867 | IC50 | 4.47 | 4.47 | 34167.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 1260.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 1540.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 6120.0 | ng.hr.mL-1 | Canis lupus familiaris |
| AUC | 6300.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 26960.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 4340.0 | ng.hr.mL-1 | Canis lupus familiaris |
| CL | 63.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 21.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 39.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 3.0 | mL.min-1.g-1 | Homo sapiens |
| Cmax | 2040.02 | nM | Rattus norvegicus |
| Cmax | 17993.44 | nM | Mus musculus |
| Cmax | 3140.26 | nM | Canis lupus familiaris |
| F | 56.0 | % | Rattus norvegicus |
| F | 87.0 | % | Mus musculus |
| F | 69.0 | % | Canis lupus familiaris |
| T1/2 | 1.9 | hr | Rattus norvegicus |
| T1/2 | 2.6 | hr | Mus musculus |
| T1/2 | 1.5 | hr | Canis lupus familiaris |
| T1/2 | 4.5 | hr | Rattus norvegicus |
| T1/2 | 4.5 | hr | Mus musculus |
| T1/2 | 4.5 | hr | Canis lupus familiaris |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 22037378 | 10.1038/nbt.1990 | Tyrosine-protein kinase ABL1 | 15 |
| 24900264 | 10.1021/ml2001455 | Mus musculus | 14 |
| 22037378 | 10.1038/nbt.1990 | Epidermal growth factor receptor | 12 |
| 22037378 | 10.1038/nbt.1990 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 10 |
| 18183025 | 10.1038/nbt1358 | Epidermal growth factor receptor | 10 |
| 26254279 | 10.18632/oncotarget.4214 | Mitogen-activated protein kinase 14 | 9 |
| 22037378 | 10.1038/nbt.1990 | Mast/stem cell growth factor receptor Kit | 8 |
| 24900264 | 10.1021/ml2001455 | Rattus norvegicus | 8 |
| 24900264 | 10.1021/ml2001455 | Canis familiaris | 8 |
| 15711537 | 10.1038/nbt1068 | Tyrosine-protein kinase ABL1 | 7 |
| 18183025 | 10.1038/nbt1358 | Tyrosine-protein kinase ABL1 | 7 |
| 22037378 | 10.1038/nbt.1990 | Receptor-type tyrosine-protein kinase FLT3 | 7 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 6 |
| 17659871 | 10.1016/j.bmcl.2007.07.016 | Mitogen-activated protein kinase 14 | 6 |
| 18183025 | 10.1038/nbt1358 | Receptor-type tyrosine-protein kinase FLT3 | 5 |
| 24900264 | 10.1021/ml2001455 | Unchecked | 5 |
| 24900264 | 10.1021/ml2001455 | Mitogen-activated protein kinase 14 | 5 |
| 33974419 | 10.1021/acs.jmedchem.0c01773 | ADMET | 5 |
| 18183025 | 10.1038/nbt1358 | Mast/stem cell growth factor receptor Kit | 5 |
| 22037378 | 10.1038/nbt.1990 | Proto-oncogene tyrosine-protein kinase receptor Ret | 4 |
Data from ChEMBL 36 via Core Engine